Drug Database
Back to search

United Kingdom· GB-APID-23861011000001101

Giotrif 50mg tablets

A afatinib product containing afatinib, registered in United Kingdom by Boehringer Ingelheim Ltd. The same ATC class is registered in 12 of our 19 countries.

ATC L01EB03

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedGiotrif 50mg tabletsATCL01EB03REGISTER NO.GB-APID-2386101100000…PACKS LISTED2CHECKEDSeptember 13, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about afatinibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Afatinib is registered in 12 of 19 countries.

Countries holding a registration under ATC L01EB03 (afatinib), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 8 of them publish a price we can compare per daily dose
Search afatinib products by name

Afatinib · ATC L01EB03

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of afatinib costs, country by country.

Normalised to the WHO defined daily dose (40 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Afatinib · price per daily dose (40 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$199.66
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Afatinib
Manufacturer
Boehringer Ingelheim Ltd
Country
United Kingdom (GB)
ATC code
L01EB03
ATC class
Afatinib
Defined daily dose
40 mg, O
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 2

  • gtin
    5012816099005
  • gtin
    5012816099487

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

170 interactions on record for afatinib.

Graded by severity as the source publishes them — 10 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check afatinib against other medicinesHow interaction checks work

Afatinib · interactions on record

170 records

  • 10 severe
  • 158 moderate
  • 2 minor

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • PexidartinibL01EX15severe
  • Aminolevulinic acidL01XD04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Afatinib in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All afatinib products

Authorised across Europe · EMA

The same active substance is authorised in 8 EEA countries. Names it is sold under:

  • Cyprus · Afatinib Afatinib, Afatinib Sapiens
  • Greece · Webrix
  • Iceland · Giotrif
  • Liechtenstein · Giotrif
  • Latvia · Afatinib, Afatinib Lotus
  • Malta · Afatinib Lotus
  • Norway · Giotrif
  • Sweden · Afatinib Lotus, Webrix

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c7826353-a681-4aba-8e1c-9b7c6797688e
GET /v1/drugs/c7826353-a681-4aba-8e1c-9b7c6797688e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "23861011000001101",
  "desc": "Giotrif 50mg tablets (Boehringer Ingelheim Ltd)",
  "form": "Oral tablet",
  "vpid": "23905211000001104",
  "source": "dmd",
  "vtm_id": "774442002",
  "strength": "50 mg",
  "substance": "Afatinib",
  "ingredient": "Afatinib dimaleate",
  "supplier_code": "2065401000001103"
}
API referenceMCP serverPlans

See everything about afatinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console